038290.KQ
Macrogen, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 12,150.00
−1.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 201.6B | 195.3B | 135.8B | 132.8B | 138.6B |
| Cost of Revenue | 127.0B | 130.2B | 88.6B | 83.6B | 85.0B |
| Gross Profit | 74.7B | 65.1B | 47.1B | 49.2B | 53.6B |
| Operating Expenses | |||||
| R&D Expense | 3.6B | — | 3.8B | 4.5B | 4.3B |
| SG&A Expense | 67.8B | 18.6B | 13.7B | 10.6B | 11.1B |
| General & Admin Expense | (13.4B) | 4.7B | 2.9B | 2.8B | 2.8B |
| Selling & Marketing Expense | 14.0B | 14.0B | 10.8B | 7.9B | 8.3B |
| Other Expenses | 48.3B | 46.4B | 36.1B | 34.5B | 32.9B |
| Total Operating Expenses | 69.8B | 65.0B | 53.6B | 49.7B | 48.3B |
| Cost and Expenses | 196.7B | 195.1B | 142.2B | 133.2B | 133.3B |
| Operating Income (EBIT) | 4.9B | 12.6M | (6.5B) | (423.1M) | 5.3B |
| Non-Operating | |||||
| Interest Income | 1.1B | 748.8M | 435.5M | 895.0M | 790.7M |
| Interest Expense | 3.3B | 2.5B | 1.2B | 983.6M | 904.4M |
| Net Interest Income | (2.2B) | (1.8B) | (768.7M) | (88.6M) | (113.8M) |
| Other Non-Op Income/Expense | 6.3B | (21.2M) | (3.4B) | (19.8B) | (34.4B) |
| Non-Operating Income (excl Interest) | (2.3B) | (2.3B) | 2.2B | 18.8B | 33.5B |
| EBT (Pre-Tax Income) | 11.2B | (8.6M) | (9.9B) | (20.2B) | (29.1B) |
| Income Tax Expense | 2.5B | 193.1M | (2.1B) | (3.5B) | (7.1B) |
| Bottom Line | |||||
| Net Income | 10.3B | 2.0B | (7.6B) | (16.8B) | (22.3B) |
| Earnings from Cont. Ops | 8.7B | (201.7M) | (7.8B) | (16.8B) | (22.0B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 10.3B | 2.0B | (7.6B) | (16.8B) | (22.3B) |
| Per Share | |||||
| Basic EPS | ₩950 | ₩187 | (₩763) | (₩1,683) | (₩2,212) |
| Diluted EPS | ₩950 | ₩187 | (₩763) | (₩1,683) | (₩2,212) |
| Revenue Per Share | ₩18,597 | ₩18,012 | ₩13,617 | ₩13,294 | ₩13,779 |
| Shares | |||||
| Basic Shares Outstanding | 10.8M | 10.8M | 10.0M | 10.0M | 10.1M |
| Diluted Shares Outstanding | 10.8M | 10.8M | 10.0M | 10.0M | 10.1M |
| Profitability Metrics | |||||
| EBITDA | 17.0B | 17.4B | 2.1B | (8.1B) | (17.2B) |
| D&A | 17.0B | 17.3B | 10.8B | 11.2B | 11.0B |
| EBIT | 4.9B | 12.6M | (8.7B) | (19.2B) | (28.2B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026